Loading stock data…
GSK.L
LSE1,845pGBX+1.50p (+0.08%)
Market ClosedLast close May 11
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GSK plc in the Healthcare sector is trading at 1,844p. The stock is currently 19% below its 52-week high of 2,282p, remaining 2.4% above its 200-day moving average. Technical signals show oversold RSI of 11 and bearish MACD signal, explaining why GSK.L maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 11) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price1,845p
Potential Upside
78.6%
Whystock Fair Value3,294p
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Hold
Mean target2,030p+10.1%
Range1,455p – 2,750p
Fundamentals
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
£82.87B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
346.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.31%
Volume
Today's trading volume
9.31M
Recent News
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
GSK's (LON:GSK) Performance Is Even Better Than Its Earnings Suggest
Investors were underwhelmed by the solid earnings posted by GSK plc ( LON:GSK ) recently. We did some digging and...
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
A Look At GSK (LSE:GSK) Valuation After Recent Share Price Weakness And Pipeline Developments
Why GSK (LSE:GSK) is on investors’ radar today GSK (LSE:GSK) has drawn attention after recent share price weakness, with the stock down about 1.4% over the past day and 5.9% over the past week, prompting closer scrutiny of its fundamentals. See our latest analysis for GSK. This recent 11.3% 1 month share price decline, despite a 3.8% year to date share price gain and a 36.6% 1 year total shareholder return, suggests momentum has cooled after a strong run for long term holders. If GSK's recent...